Met Life Investment Management, LLC Akebia Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $18 Billion
  • Q4 2024

A detailed history of Met Life Investment Management, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 104,030 shares of AKBA stock, worth $197,657. This represents 0.0% of its overall portfolio holdings.

Number of Shares
104,030
Previous 68,064 52.84%
Holding current value
$197,657
Previous $89,000 116.85%
% of portfolio
0.0%
Previous 0.0%

Shares

54 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
BUY
$1.26 - $2.13 $45,317 - $76,607
35,966 Added 52.84%
104,030 $193,000
Q3 2024

Nov 13, 2024
BUY
$0.94 - $1.55 $13,072 - $21,555
13,907 Added 25.68%
68,064 $89,000
Q2 2024

Aug 13, 2024
BUY
$0.86 - $1.63 $46,575 - $88,275
54,157 New
54,157 $55,000
Q2 2022

Aug 11, 2022
SELL
$0.32 - $0.67 $27,259 - $57,074
-85,186 Closed
0 $0
Q1 2022

May 10, 2024
BUY
$0.72 - $2.93 $61,333 - $249,594
85,186 New
85,186 $61,000
Q1 2022

Jun 20, 2023
BUY
$0.72 - $2.93 $61,333 - $249,594
85,186 New
85,186 $61,000
Q1 2022

Mar 22, 2023
BUY
$0.72 - $2.93 $39,160 - $159,359
54,389 Added 176.6%
85,186 $61,000
Q1 2022

May 12, 2022
BUY
$0.72 - $2.93 $39,160 - $159,359
54,389 Added 176.6%
85,186 $61,000
Q4 2021

May 17, 2024
SELL
$2.26 - $3.34 $74,419 - $109,982
-32,929 Reduced 51.67%
30,797 $69,000
Q4 2021

Jun 21, 2023
BUY
$2.26 - $3.34 $69,601 - $102,861
30,797 New
30,797 $69,000
Q4 2021

Mar 22, 2023
SELL
$2.26 - $3.34 $74,419 - $109,982
-32,929 Reduced 51.67%
30,797 $69,000
Q4 2021

Feb 15, 2022
SELL
$2.26 - $3.34 $74,419 - $109,982
-32,929 Reduced 51.67%
30,797 $70,000
Q3 2021

May 17, 2024
BUY
$2.35 - $3.88 $73,425 - $121,230
31,245 Added 96.19%
63,726 $183,000
Q3 2021

Jun 21, 2023
BUY
$2.35 - $3.88 $149,756 - $247,256
63,726 New
63,726 $183,000
Q3 2021

Mar 22, 2023
BUY
$2.35 - $3.88 $73,425 - $121,230
31,245 Added 96.19%
63,726 $183,000
Q3 2021

Nov 15, 2021
BUY
$2.35 - $3.88 $73,425 - $121,230
31,245 Added 96.19%
63,726 $184,000
Q2 2021

May 17, 2024
SELL
$2.83 - $4.2 $80,414 - $119,343
-28,415 Reduced 46.66%
32,481 $123,000
Q2 2021

Jun 21, 2023
BUY
$2.83 - $4.2 $91,921 - $136,420
32,481 New
32,481 $123,000
Q2 2021

Mar 22, 2023
SELL
$2.83 - $4.2 $80,414 - $119,343
-28,415 Reduced 46.66%
32,481 $123,000
Q2 2021

Aug 16, 2021
SELL
$2.83 - $4.2 $80,414 - $119,343
-28,415 Reduced 46.66%
32,481 $123,000
Q1 2021

May 17, 2024
BUY
$2.92 - $5.06 $177,816 - $308,133
60,896 New
60,896 $205,000
Q1 2021

Jun 26, 2023
BUY
$2.92 - $5.06 $177,816 - $308,133
60,896 New
60,896 $206 Million
Q1 2021

Mar 22, 2023
BUY
$2.92 - $5.06 $84,096 - $145,728
28,800 Added 89.73%
60,896 $205,000
Q1 2021

May 14, 2021
BUY
$2.92 - $5.06 $84,096 - $145,728
28,800 Added 89.73%
60,896 $206,000
Q4 2020

May 24, 2024
BUY
$2.22 - $3.78 $8,433 - $14,360
3,799 Added 13.43%
32,096 $89,000
Q4 2020

Jun 22, 2023
BUY
$2.22 - $3.78 $71,253 - $121,322
32,096 New
32,096 $89,000
Q4 2020

Mar 22, 2023
BUY
$2.22 - $3.78 $8,433 - $14,360
3,799 Added 13.43%
32,096 $89,000
Q4 2020

Feb 16, 2021
BUY
$2.22 - $3.78 $8,433 - $14,360
3,799 Added 13.43%
32,096 $90,000
Q3 2020

May 24, 2024
SELL
$2.39 - $13.08 $71,413 - $390,830
-29,880 Reduced 51.36%
28,297 $71 Million
Q3 2020

Jun 26, 2023
BUY
$2.39 - $13.08 $67,629 - $370,124
28,297 New
28,297 $71,000
Q3 2020

Mar 22, 2023
SELL
$2.39 - $13.08 $71,413 - $390,830
-29,880 Reduced 51.36%
28,297 $71,000
Q3 2020

Nov 13, 2020
SELL
$2.39 - $13.08 $71,413 - $390,830
-29,880 Reduced 51.36%
28,297 $71,000
Q2 2020

May 24, 2024
BUY
$6.67 - $13.58 $388,040 - $790,043
58,177 New
58,177 $790 Million
Q2 2020

Jun 26, 2023
BUY
$6.67 - $13.58 $388,040 - $790,043
58,177 New
58,177 $790,000
Q2 2020

Mar 22, 2023
BUY
$6.67 - $13.58 $39,693 - $80,814
5,951 Added 11.39%
58,177 $790,000
Q2 2020

Aug 14, 2020
BUY
$6.67 - $13.58 $39,693 - $80,814
5,951 Added 11.39%
58,177 $790,000
Q1 2020

Jul 12, 2023
BUY
$4.1 - $10.24 $214,126 - $534,794
52,226 New
52,226 $395,000
Q1 2020

Mar 22, 2023
BUY
$4.1 - $10.24 $43,505 - $108,656
10,611 Added 25.5%
52,226 $395,000
Q1 2020

May 15, 2020
BUY
$4.1 - $10.24 $43,505 - $108,656
10,611 Added 25.5%
52,226 $396,000
Q4 2019

Jul 12, 2023
BUY
$3.16 - $6.73 $131,503 - $280,068
41,615 New
41,615 $263,000
Q4 2019

Mar 22, 2023
SELL
$3.16 - $6.73 $49,646 - $105,735
-15,711 Reduced 27.41%
41,615 $263,000
Q4 2019

Feb 14, 2020
SELL
$3.16 - $6.73 $49,646 - $105,735
-15,711 Reduced 27.41%
41,615 $263,000
Q3 2019

Jul 12, 2023
BUY
$3.55 - $5.4 $203,507 - $309,560
57,326 New
57,326 $224,000
Q3 2019

Mar 22, 2023
BUY
$3.55 - $5.4 $59,348 - $90,277
16,718 Added 41.17%
57,326 $224,000
Q3 2019

Nov 14, 2019
BUY
$3.55 - $5.4 $59,348 - $90,277
16,718 Added 41.17%
57,326 $225,000
Q2 2019

Jul 12, 2023
BUY
$4.1 - $8.05 $235,036 - $461,474
57,326 New
57,326 $277,000
Q1 2019

Jul 13, 2023
BUY
$5.41 - $8.73 $219,689 - $354,507
40,608 New
40,608 $332,000
Q4 2018

Jul 13, 2023
BUY
$5.39 - $9.15 $218,877 - $371,563
40,608 New
40,608 $224,000
Q4 2018

Mar 22, 2023
BUY
$5.39 - $9.15 $12,127 - $20,587
2,250 Added 5.87%
40,608 $224,000
Q4 2018

Feb 14, 2019
BUY
$5.39 - $9.15 $12,127 - $20,587
2,250 Added 5.87%
40,608 $225,000
Q3 2018

Jul 13, 2023
BUY
$7.44 - $10.65 $159,431 - $228,218
21,429 New
21,429 $189,000
Q3 2018

Mar 22, 2023
BUY
$7.44 - $10.65 $285,383 - $408,512
38,358 New
38,358 $338,000
Q3 2018

Nov 14, 2018
BUY
$7.44 - $10.65 $125,951 - $180,293
16,929 Added 79.0%
38,358 $339,000
Q4 2017

Feb 15, 2018
BUY
$14.24 - $19.59 $305,148 - $419,794
21,429
21,429 $319,000

Others Institutions Holding AKBA

# of Institutions
128
Shares Held
63.3M
Call Options Held
50.6K
Put Options Held
203K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $349M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email